GCTBGiant Cell Tumor of Bone
GCTBGreen Cane Trash Blanketing (sugar industry)
GCTBGold Coast Tourism Bureau (Australia)
GCTBGroupement des Constructeurs en Terre Battue (French Clay Builders Group)
GCTBGrover Chasers Touring Bunch (motorcycle club; New Zealand)
GCTBGibson Cognitive Test Battery (skills screening)
GCTBGarbay Courtier en Travaux du Bâtiment (French broker)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
GCTB most commonly occurs in the long bones, namely the distal femur, proximal tibia, and distal radius, altogether accounting for 50% of the cases [2].
To investigate the underlying function of miR-16-5p in GCT, we first detected its expression in patients with GCTB. The results showed that osteoclast formation increased, whereas miR-16-5p expression decreased significantly with the severity of bone destruction (Figures 1(a)-1(h)).
Giant cell tumor of the bone (GCTB) was first described by Jaffe in 1940 as one of the common primary bone tumors; while its source remained uncertain, it may originate from the mesenchymal tissues of the bone marrow.1 GCTB has aggressive features, with huge corrosive destruction of the sclerotin, which left rare tendency of reactive new bone formation and healing; However, GCTB may also penetrate the cortical bone and form soft tissue masses, leading to high recurrence rates after curettage.
World Health Organization (WHO) classifies giant cell tumor of bone (GCTB) as a benign, locally aggressive tumor.
During the surgical procedure, first a biopsy was perform which revealed benign multinucleated giant cells in a mononuclear stroma, while the mononuclear cells showed moderate atypia and extensive hemosiderin deposition, suggestive of GCTB. Based on this benign diagnoisis, aggressive curettage and high speed burring were performed to remove the tumor.
Only two cases of GCTB have ever been reported in HIV-positive patients, and neither of these cases required a massive transfusion of blood products." [1,5]
GCTB typically affects individuals between the ages of 20 to 40.
XGEVA's FDA approval is based on positive results from two open-label trials that enrolled patients with GCTB that was either recurrent, unresectable, or for which planned surgery was likely to result in severe morbidity.
The objective of this work was to measure returns and decomposition of sugarcane trash under the GCTB system, in terms of dry matter (DM), C, and N, in contrasting climatic conditions.
The design is based on the GCTB and GBTC oscillators.
Different diagnoses for bone tumors that develop in the epiphysis are mostly benign lesions, such as chondroblastoma, giant cell tumor of bone (GCTB), and intraosseous ganglion.